Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. (NASDAQ: SNES) generates news as a biotechnology company focused on fertility control for rodent management. Its announcements frequently highlight developments related to ContraPest®, Evolve Rat, and Evolve Mouse Birth Control, which are described as contraceptive products for rats and mice that fit into integrated pest management programs and reduce reliance on traditional rodenticides.
Investors and observers following SNES news will see regular updates on financial performance and growth in Evolve rodent birth control products. Quarterly press releases report record revenues, gross profit margins, and the share of revenue contributed by Evolve-branded products, as well as commentary on adjusted EBITDA and cash balances. These releases often discuss progress toward profitability and the impact of multi-channel distribution strategies.
Company news also covers operational and commercial milestones. Examples include the launch of Evolve Rat Birth Control on major e-commerce platforms and home improvement retailer websites, expanded retail coverage through partners and wholesalers, and municipal pilot deployments in U.S. cities. Additional updates describe international distribution relationships, such as the appointment of the Belize Raptor Center as an official distributor following regulatory approval in Belize.
Regulatory and capital markets activities appear in SenesTech’s news flow as well. The company issues press releases on warrant exercises, gross proceeds from financings, and participation in investor conferences. For readers tracking SNES, this news page offers a way to monitor how SenesTech reports on product adoption, distribution channels, municipal and community programs, and financing events over time.
SenesTech, Inc. (NASDAQ: SNES) has gained recognition in TIME Magazine for its innovative rodent control product, ContraPest. This EPA registered contraceptive has demonstrated a significant impact, reducing rat populations by up to 90% in various programs, including a new initiative in Ferndale, MI. The CEO, Joel Fruendt, highlighted ContraPest's potential to transform pest management globally. Parker Eco-Pest Control reported similar success in Seattle, with businesses experiencing rodent-free conditions for the first time. The article emphasizes ContraPest as a sustainable solution to tackle rat infestations through fertility control.
SenesTech, Inc. (NASDAQ: SNES) reported strong financial results for 2022, with product sales exceeding $1 million and an overall increase of 77% year-on-year. Revenue reached $1.0 million, a 70% rise from 2021, while gross profit was $464,000. Despite these gains, the company posted a net loss of $9.7 million. The fourth quarter saw revenue of $297,000, up 54%, with product sales increasing 76%. Significant growth was driven by the e-commerce platform and contracts with zoos and government agencies. The recent launch of the Elevate Bait System™ is expected to create further opportunities, particularly within agricultural markets.
SenesTech (NASDAQ: SNES), a leader in rodent fertility control, has announced its collaboration with Danish company TriptoBIO to develop biosynthetic triptolide, an active ingredient in their EPA-registered contraceptive, ContraPest. This partnership aims to enhance the efficiency and cost-effectiveness of ContraPest by ensuring consistent quality and reducing production costs compared to botanically sourced triptolide from China. CEO Joel Fruendt highlighted the potential for improved market expansion and sustainability through this initiative, which aligns with the company's mission to advance pest management practices.
SenesTech, Inc. (NASDAQ: SNES) is set to release its financial results for the fourth quarter and fiscal year 2022 after market close on March 16, 2023. A conference call will follow at 5:00 pm ET to discuss the outcomes. The company's proprietary technology, ContraPest, is focused on managing rodent populations through fertility control rather than extermination. This unique approach aligns with sustainable pest management practices. Investors can join the conference call via telephone or through a live webcast available on SenesTech's Investor Relations website.
SenesTech, Inc. (NASDAQ: SNES) reported significant findings on its rodent fertility control product, ContraPest, at the recent Vertebrate Pest Conference (VPC). Major highlights include a 95% reduction in rat activity when ContraPest is used in integrated pest management programs. Independent studies also indicated a 98% decline in rat populations at an animal rescue facility and an 80% reduction at another location. Customers have noted reduced economic losses, enhancing the product's acceptance. SenesTech aims to leverage this surge for growth acceleration in 2023, supported by positive customer feedback.
SenesTech (NASDAQ: SNES) announced the appointment of Nicole Williams as its new Chief Revenue Officer as part of a broader restructuring to enhance sales and commercialization efforts. Following a year of record revenue, the company is expanding its field sales organization to seven teams and is focused on customer acquisition in 2023. An E-Commerce Manager will be incorporated to improve product education and accessibility. The CEO highlighted the goal of accelerating growth beyond a 2X growth rate after a successful 2022. The company is set to release its fourth quarter financials in March 2023.
SenesTech, Inc. (NASDAQ: SNES) announced that ContraPest, the only EPA registered contraceptive for rats, has been approved for General Use by the New York State Department of Environmental Conservation. This decision removes the "Restricted Use Pesticide" label, significantly broadening the market for ContraPest in New York, allowing non-licensed individuals to apply it. New York is now the 49th state to approve this change, joining Washington D.C. and various U.S. territories. CEO Joel Fruendt emphasized the importance of ContraPest in reducing rat populations, particularly as New York City prioritizes rat control efforts.
SenesTech, Inc. (NASDAQ: SNES) announced its participation in the Lytham Partners Investor Select Conference on January 31, 2023. The management team will host one-on-one meetings with investors and present its cutting-edge technology for controlling animal pest populations through fertility control. The live presentation will be available at 9:00 AM ET on the company’s website, alongside archived content for later viewing. Interested parties can arrange meetings through Lytham Partners. SenesTech focuses on sustainable pest control, aiming to reduce rodent populations without harmful methods, leveraging their patented product, ContraPest.
SenesTech (NASDAQ: SNES) has granted inducement equity awards to its new CEO, Joel Fruendt, and two other employees, aligning with Nasdaq Listing Rule 5635(c)(4). Fruendt received 18,799 restricted stock units and options to purchase 71,500 shares at an exercise price of $2.66. The other employees, Dan Palasky and Alice Myton, received options to purchase 26,500 and 1,000 shares, respectively. All options will vest over three years, aiming to enhance staff retention and attract talent. This strategic move underscores SenesTech's commitment to growth in rodent fertility control with their EPA registered product, ContraPest.
SenesTech (NASDAQ: SNES) has announced a significant deployment of its EPA registered contraceptive, ContraPest, at the Los Angeles Zoo. The initial rollout involves 17 bait stations, expanding to over 250 as confidence grows. ContraPest has shown up to 90% efficacy improvement over traditional pest control methods, addressing issues common to zoo environments. This deployment is part of a market expansion opportunity, as SenesTech reports that the zoo and sanctuary vertical has grown over 300% in the past year, now serving nearly 70 customers.